Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Azelastine/budesonide intranasal - Sedor

Next Previous
Drug Profile

Azelastine/budesonide intranasal - Sedor

Alternative Names: Captisol-enabled™ Budesonide + Azelastine nasal spray - Sedor; CDX-313; LGD-313

Latest Information Update: 04 Oct 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CyDex Pharmaceuticals
  • Developer Sedor Pharmaceuticals
  • Class Glucocorticoids; Phthalazines; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Histamine H1 receptor antagonists; Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Seasonal allergic rhinitis

Most Recent Events

  • 04 Oct 2017 Azelastine/budesonide is still at phase II development stage for Seasonal allergic rhinitis in Canada (Intranasal) (Sedor Pharmaceuticals website, October 2017)
  • 08 Dec 2015 Captisol-enabled™ azelastine/budesonide licensed to RODES Pharmaceuticals in USA
  • 08 Dec 2015 RODES plans a phase I trial for Seasonal allergic rhinitis in USA (Intranasal)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top